Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Prognostic Significance of Survivin

Prognostic Significance of Survivin ORIGINAL ARTICLE Prognostic Significance of Survivin Polymorphisms on Non-small Cell Lung Cancer Survival Juncheng Dai, MD, PhD,* Guangfu Jin, MD, PhD,* Jing Dong, MD, PhD,* Yijiang Chen, MD, PhD,† Lin Xu, MD, PhD,‡ Zhibin Hu, MD, PhD,*§ and Hongbing Shen, MD, PhD*§ on-small cell lung carcinoma (NSCLC) is the leading Introduction: Survivin is an apoptotic inhibitor, involves in regu- Ncause of cancer death worldwide, and the prognosis of lation of apoptosis and cell cycle progression, and its polymor- NSCLC is still poor with a 5-year survival rate of less than phisms may influence the development and progression of cancer. 9% in the developing countries. The current model by using This study evaluated the impact of the survivin gene polymorphisms information of clinical diagnosis, patient characteristics com- on survival of non-small cell lung cancer (NSCLC) patients. bined with pathology or stage, cannot accurately predict Methods: In this case-cohort follow-up study, a total of 568 NSCLC patient outcome. To further understand the biology of patients were investigated and 12 single nucleotide polymorphisms NSCLC development and prognosis, the information from in survivin gene were genotyped by using the Illumina GoldenGate single nucleotide polymorphisms (SNPs) in genes at molec- platform. ular level is http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Prognostic Significance of Survivin

Shen, Hongbing
Journal of Thoracic Oncology , Volume 5 (11) – Nov 1, 2010
Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/prognostic-significance-of-survivin-Db9cgrNsgE

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864
DOI
10.1097/JTO.0b013e3181f18cb9
pmid
20881643
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Prognostic Significance of Survivin Polymorphisms on Non-small Cell Lung Cancer Survival Juncheng Dai, MD, PhD,* Guangfu Jin, MD, PhD,* Jing Dong, MD, PhD,* Yijiang Chen, MD, PhD,† Lin Xu, MD, PhD,‡ Zhibin Hu, MD, PhD,*§ and Hongbing Shen, MD, PhD*§ on-small cell lung carcinoma (NSCLC) is the leading Introduction: Survivin is an apoptotic inhibitor, involves in regu- Ncause of cancer death worldwide, and the prognosis of lation of apoptosis and cell cycle progression, and its polymor- NSCLC is still poor with a 5-year survival rate of less than phisms may influence the development and progression of cancer. 9% in the developing countries. The current model by using This study evaluated the impact of the survivin gene polymorphisms information of clinical diagnosis, patient characteristics com- on survival of non-small cell lung cancer (NSCLC) patients. bined with pathology or stage, cannot accurately predict Methods: In this case-cohort follow-up study, a total of 568 NSCLC patient outcome. To further understand the biology of patients were investigated and 12 single nucleotide polymorphisms NSCLC development and prognosis, the information from in survivin gene were genotyped by using the Illumina GoldenGate single nucleotide polymorphisms (SNPs) in genes at molec- platform. ular level is

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Nov 1, 2010

References

  • Global cancer statistics, 2002
    Parkin
  • Survivin apoptosis: an interloper between cell death and cell proliferation in cancer
    Altieri
  • X-linked IAP is a direct inhibitor of cell-death proteases
    Deveraux
  • Conservation of baculovirus inhibitor of apoptosis repeat proteins (BIRPs) in viruses, nematodes, vertebrates and yeasts
    Uren
  • A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
    Ambrosini
  • Survivin, versatile modulation of cell division and apoptosis in cancer
    Altieri
  • Validating survivin as a cancer therapeutic target
    Altieri
  • Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis
    Blanc-Brude
  • Survivin—an anti-apoptosis protein: its biological roles and implications for cancer and beyond
    Chiou
  • A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers
    Monzo
  • A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells
    Xu
  • Survivin promoter polymorphism and cervical carcinogenesis
    Borbely
  • Correlation of -31G/C polymorphisms of survivin promoter to tumorigenesis of gastric carcinoma
    Cheng
  • Polymorphisms in the survivin gene and the risk of lung cancer
    Jang
  • The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population
    Yang
  • A 3′-untranslated region polymorphism in IGF1 predicts survival of non-small cell lung cancer in a Chinese population
    Zhang
  • Genetic variants in MGMT and risk of lung cancer in Southeastern Chinese: a haplotype-based analysis
    Hu
  • Quantitatively determined survivin expression levels are of prognostic value in human gliomas
    Chakravarti
  • Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53
    Kappler
  • Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer
    Kawasaki
  • Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer
    Satoh
  • Expression of survivin and its relationship to loss of apoptosis in breast carcinomas
    Tanaka
  • Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice
    Floyd
  • Survivin -31G/C promoter polymorphism and sporadic colorectal cancer
    Gazouli
  • Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer
    Han
  • Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer
    Nakano
  • Analysis of Bcl-2, Bax and Survivin genes in uterine cancer
    Saitoh
  • CpG island methylation of DNA damage response genes in advanced ovarian cancer
    Teodoridis
  • Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer
    Vegran
  • Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia
    Wagner
  • Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma
    Yang
  • EM011 activates a survivin-dependent apoptotic program in human non-small cell lung cancer cells
    Karna
  • Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma
    Krepela
  • Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients
    Chen
  • The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures
    Fan
  • Transcriptional analysis of human survivin gene expression
    Li
  • Control of apoptosis and mitotic spindle checkpoint by survivin
    Li
  • Anti-apoptosis gene, survivin, and prognosis of neuroblastoma
    Adida
  • An IAP-IAP complex inhibits apoptosis
    Dohi
  • The Survivin saga goes in vivo
    Reed
  • Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma
    Schlette
  • Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions
    Zaffaroni
  • Downregulation of survivin and aurora a by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy
    Biran
  • Recent advances in anti-survivin treatments for cancer
    Kanwar
  • Survivin: a new target for anti-cancer therapy
    Ryan